tirzepatide and aod 9604 together aod9604 semaglutide Peptide Therapy AOD-9604 vs MOTS-c vs Tesamorelin
Description
Mounjaro (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities
Additional trials for tirzepatide will include its effect in people who have non-alcoholic fatty liver disease and congestive heart failure
Results Over a median of 4 years, in the tirzepatide group versus the dulaglutide group: The primary composite endpoint occurred in 12.2% versus 13.1% (HR 0.92
Be sure to talk to your healthcare provider about Rybelsus and how to take it
